Abbott Laboratories $ABT Shares Sold by Courier Capital LLC

Courier Capital LLC lowered its position in Abbott Laboratories (NYSE:ABT) by 42.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,642 shares of the healthcare product maker’s stock after selling 13,137 shares during the period. Courier Capital LLC’s holdings in Abbott Laboratories were worth $1,744,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its position in shares of Abbott Laboratories by 14.1% during the third quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock worth $8,339,000 after buying an additional 10,431 shares during the period. Juncture Wealth Strategies LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at approximately $658,000. Aureus Asset Management LLC raised its position in Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after buying an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. lifted its stake in Abbott Laboratories by 786.0% in the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after acquiring an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in Abbott Laboratories during the 2nd quarter worth approximately $4,889,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ABT. BTIG Research raised their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Wells Fargo & Company boosted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $118.88.

Abbott Laboratories Stock Up 0.9%

ABT stock traded up $0.89 during mid-day trading on Tuesday, reaching $102.71. The company had a trading volume of 9,863,158 shares, compared to its average volume of 11,308,400. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The stock has a 50 day simple moving average of $106.08 and a two-hundred day simple moving average of $98.27. The company has a market capitalization of $177.72 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 1.85 and a beta of 0.59. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $133.34.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the previous year, the firm earned $1.26 EPS. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s payout ratio is presently 81.55%.

About Abbott Laboratories

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.